Innate Pharma Secures €15 Million Sanofi Investment and Advances Key Therapies

Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.

Innate Pharma SA announced a significant €15 million investment from Sanofi, enhancing their ongoing partnership and supporting the development of the BCMA targeting ANKET® program in autoimmune indications. The first quarter of 2025 saw notable progress with the first patient dosed in a Phase 1 study for IPH4502, a Nectin-4 ADC, and the FDA granting Breakthrough Therapy Designation to lacutamab for Sézary syndrome. These advancements, along with a strengthened financial position, position Innate Pharma to deliver innovative therapies and maintain a cash runway into mid-2026.

The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma SA is a biotechnology company based in Marseille, France, specializing in the development of immunotherapies for cancer treatment. The company focuses on creating innovative therapies using its proprietary ANKET® platform, which develops next-generation, multi-specific NK cell engagers, and other antibody-based treatments.

Average Trading Volume: 169,907

Technical Sentiment Signal: Sell

Current Market Cap: €185.2M

For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.